Health
Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business
Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…
Continue Reading
-
General21 hours agoMigrants raise concerns over Australia’s English tests for visa applicants
-
Noosa News23 hours agoSunshine Coast women celebrated at 26th annual business awards
-
Noosa News15 hours agoThe only person detained at Brisbane’s Palestine rally
-
Noosa News24 hours agoNew FLC President has regional lens – Proctor